摘要
目的评估内脏胸膜侵犯(VPI)对术后ⅢA/N2M0期非小细胞肺癌(NSCLC)病人生存的影响。方法利用监测、流行病学和最终结果(SEER)数据库,筛选2010~2015年间接受手术的ⅢA/N2M0期NSCLC病人。Cox比例风险回归确定与生存相关的因素。通过Kaplan-Meier分析非VPI组和VPI组之间的总体生存(OS)。结果VPI预后相关的因素包括种族(P<0.001)和腺癌(P<0.001)。与非VPI组比较,VPI是OS的重要独立预后因素(HR,1.432;95%CI,1.082~1.573,P=0.006)。结论VPI对术后ⅢA/N2期NSCLC病人是一个不良的预后因素。研究表明,化疗显著提高了术后ⅢA/N2M0期NSCLC病人的总体生存率,降低肺癌的相关死亡率,尤其是非VPI病人。
Objective To evaluate the effect of VPI on the survival of patients with postoperative stageⅢA/N2 M0 non-small cell lung cancer.Methods Using the Surveillance,Epidemiology,and Final Results(SEER)database,we screened patients with stageⅢA/N2 M0 non-small cell lung cancer who underwent surgery between 2010 and 2015.Cox proportional hazards regression is used to determine factors related to survival.Kaplan-Meier was used to analyze cancer-specific survival(CSS)and overall survival(OS)between the non-VPI group and the VPI group.Results Prognostic factors related to the VPI included race(P<0.001)and adenocarcinoma(P<0.001).VPI was an important independent prognostic factor of OS(HR,1.432;95%CI,1.082-1.573,P=0.006).Conclusion Our results show that VPI is a poor prognostic factor in patients with postoperative stageⅢA/N2 non-small cell lung cancer.Studies have shown that chemotherapy significantly improves the overall survival rate of patients with stageⅢA/N2 M 0 non-small cell lung cancer after surgery,and reduces the related mortality of lung cancer,especially for non-VPI patients.
作者
阮添
李昌盛
杨泽天
周雪峰
王乐
RUAN Tian;LI Changsheng;YANG Zetian(Department of Thoracic Surgery,Zhongnan Hospital of Wuhan University,Wuhan 430071,China;不详)
出处
《临床外科杂志》
2022年第5期448-452,共5页
Journal of Clinical Surgery
关键词
非小细胞肺癌
内脏胸膜侵犯
预后
non-small-cell-lung-cancer
visceral pleural invasion
survival prognosis
